ERBB3 and gastric cancer: To this end, we assess the efficacy of the combinational treatment of GB235 and Trastuzumab in the NCI-N87 xenograft model, as inhibition of HER3 in the HER2-positive gastric cancers exhibits a promising efficacy32.